molecules of the month


short engagement, selective CDK9 kinase inh.

IV treatment in Ph. I for RR-heme cancers

shortened t1/2 from prior preclin. candidate

J. Med. Chem., Dec. 11, 2020

AstraZeneca, Cambridge, UK / Boston, MA

Structure of AZD4573, a potent and selective inhibitor of CDK9
1 min read

AstraZeneca selective CDK9 kinase inhibitor

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: